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Background. Recombinant human insulin-like growth factor-I
(rhIGF-I) accelerates recovery from acute renal failure (ARF) in
rats. IGF-I acts through the IGF-I receptor (IGF-IR) and its
actions may be modified by IGF-I binding proteins (IGFBPs). It
therefore would be of value to determine the effects of both ARF
and rhIGF-I treatment on serum IGFBPs and mRNA for IGFBPs
and IGF-IR.
Methods. Rats with ARF and sham-operated control rats were
randomized to receive rhIGF-I or vehicle injections thrice daily
for 72 to 74 hours starting five hours after surgery. Serum IGFPBs
1 to 6 were measured serially, and mRNA for IGFBPs 1 to 6 and
for IGF-IR were measured in several tissues obtained 72 to 74
hours after surgery.
Results. At 72 to 74 hours, serum IGFBP-1 and IGFBP-2 levels
were higher in rhIGF-I treated rats. Serum IGFBP-3 was affected
by both ARF and rhIGF-I. IGFBP-4 rose transiently only in ARF
groups. At 72 to 74 hours, mRNA for several IGFBPs was
reduced in renal cortex of ARF rats. Low mRNA for IGFBP-4
and -6 was observed in renal medulla of the ARF rats, particularly
in comparison to the sham-operated rats receiving vehicle. Renal
medullary IGFBP-2 mRNA was decreased in ARF and sham rats
given rhIGF-I as compared to sham animals given vehicle. He-
patic IGFBP-2 mRNA was higher in both rhIGF-I treated groups
versus those given vehicle. Otherwise, there were no differences in
IGFBP mRNAs among the four groups in lung, heart, and
skeletal muscle. IGF-IR mRNA was decreased in renal cortex and
medulla of both ARF groups and was not detected in liver in any
group.
Conclusions. Thus, ARF and rhIGF-I treatment each affected
certain serum IGFBPs and jointly affected some IGFBPs. ARF
suppressed gene transcription for renal cortical and medullary
IGF-IR and some IGFBPs. rhIGF-I independently affected some
renal cortical or medullary IGFBP mRNAs. rhIGF-I increased
hepatic IGFBP-2 mRNA and serum IGFBP-2. These effects of
ARF or rhIGF-I may influence rhIGF-I actions in rats with
ischemic ARF.
Insulin-like growth factor I (IGF-I) is a peptide growth
factor with metabolic [1], mitogenic and vasoactive prop-
erties [2, 3]. In the kidney, IGF-I increases renal blood flow
and glomerular filtration rate (GFR) [4], stimulates mito-
genicity [5] and decreases apoptosis of tubular cells [3]. In
the proximal tubule, IGF-I is not expressed [6]. However,
after renal ischemic injury, IGF-I is transiently expressed in
proximal tubular cells and in macrophages, suggesting an
important role for IGF-I in the repair from acute tubular
injury [6, 7]. Indeed, administration of IGF-I to several
animal models of ARF accelerates the recovery of renal
function, improves renal histology and may also decrease
the catabolic state [8–12].
It is believed that the actions of IGF-I are regulated by
one or more of six IGF-I binding proteins (IGFBPs) and
also by the IGF type I receptor (IGF-IR) [3]. Hence, there
has been considerable interest in the response of IGFBPs
and the expression of IGF-IR in the kidney with ARF
[12–14]. Moreover, the concentrations of IGFBPs in serum
and the expression of IGFBP mRNAs and IGF-IR mRNA
in nonrenal tissues after the induction of ARF have not
been systematically evaluated, particularly when rats are
receiving exogenous IGF-I. Since IGF-I has been adminis-
tered in research protocols to animals and humans with
ischemic ARF, we investigated the response of serum
IGFBPs and tissue IGFBP mRNAs and IGF-IR mRNA in
rats that were receiving subcutaneous injections of recom-
binant human IGF-I (rhIGF-I) or vehicle. The following
hypotheses were tested: (1) In rats, ischemic ARF alters the
concentrations of certain IGFBPs in serum and the expres-
sion of mRNA for IGFBPs and the IGF-IR in the kidney
and other tissues. (2) Treatment with rhIGF-I indepen-




Male Sprague-Dawley rats weighing 200 to 250 g were
studied. Rats were housed in metabolic cages from 24
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hours before surgery until they were killed 72 to 74 hours
postoperatively. Animals were randomly assigned to un-
dergo one of two surgical procedures: creation of ARF or
sham operation (SO). Rats were allowed free access to rat
chow until surgery. At 9:00 a.m. to 10:00 a.m., rats were
anesthetized with ketamine (87 mg/kg body wt) and xyla-
zine (13 mg/kg body wt). ARF was produced by an anterior
abdominal incision and clamping of both renal pedicles for
45 minutes with a baby Dieffenbach clamp. SO rats under-
went laparotomy for a similar duration of time, abdominal
incision length, and manipulation of organs, but the renal
pedicles were not clamped. Only two rats died spontane-
ously. Both had ARF and died from abdominal bleeding
within 24 hours after surgery, after one rhIGF-I injection.
The ARF and SO rats were randomly assigned to receive
subcutaneous injections of either rhIGF-I (Chiron Thera-
peutics, Emeryville, CA, USA), 50 mg/100 g body wt (that
is, ARF1IGF-I or SO1IGF-I), or a similar volume of
vehicle (V, 0.9% saline; that is, ARF1V or SO1V). The
injections were given three times per day for a total of nine
doses starting five hours after surgery and continuing at
8:00 p.m., 8:00 a.m. and 2:00 p.m. each day. Six animals
were studied in each of the four groups. ARF and SO rats
were fasted during the 72 to 74 hours after surgery except
for free access to tap water containing 5% dextrose mono-
hydrate. Tail blood samples were drawn before surgery and
at 5, 24, 48 and 72 to 74 hours after surgery. Rats were
killed by decapitation 72 to 74 hours after surgery, and
liver, lung, heart, quadriceps muscle and kidney (cortex and
medulla) tissues were taken and immediately processed as
follows. Serum creatinine was measured using the Sigma kit
(Sigma-Aldrich Corporation, St. Louis, MO, USA) accord-
ing to the manufacturer’s instructions.
Semiquantification of serum IGFBPs by Western blotting
Western ligand blotting was performed as previously
described [15, 16] with modifications to improve band
separation. Serum samples (2 ml/lane) were diluted 1:10 in
non-reducing Laemmli sample buffer [17], boiled for three
minutes and separated at room temperature with constant
(12 mAmp) current for about 15 hours on 12% SDS-
polyacrylamide gels using a Bio-Rad Protean II electro-
phoresis system (Richmond, CA, USA). Proteins were
electrotransferred onto nitrocellulose at constant (0.4
Amp) current for 24 hours at room temperature using a
Bio-Rad Trans Blot electrophoretic transfer cell. The
membranes were blocked in the TBS buffer (20 mM Tris, 50
mM NaCl, pH 7.4) containing 3% wt/vol bovine serum
albumin (BSA) at room temperature for 12 hours, and then
incubated overnight at 4°C with 1.7 mCi of 125I-labeled
IGF-I (Amersham, Arlington Heights, IL, USA) in 15 ml of
3% wt/vol BSA in TTBS buffer (TBS buffer with 0.05%
(vol/vol) Tween 20). The membranes were then washed in
TBS, dried and exposed to Fuji RX x-ray film for three to
four days at 270°C with Dupont Cromex intensifying
screens.
To identify the binding proteins with a molecular weight
of about 30 kD that were visualized by Western ligand
blotting, Western immunoblots for serum IGFBP-1 and -2
were performed on the same membranes after completion
of the Western ligand blottings [16]. Briefly, membranes
were washed in TBS, blocked in TBSM [TBS buffer with in
5% (wt/vol) nonfat dry milk] at room temperature for one
hour, and incubated overnight at 4°C with rabbit antibovine
IGFBP-2 antibody (1:2,000; Upstate Biotechnology Incor-
porated, Lake Placid, NY, USA) or rabbit antirat IGFBP-1
antibody (1:800; gift from Dr. T. Unterman, Chicago, IL,
USA) in TTBSM buffer [TTBS buffer with 3% (wt/vol)
nonfat dry milk]. After washes with TTBS buffer, the
membranes were incubated with biotinylated goat antirab-
bit IgG (1:3,000) and HRSP-Streptavidin (1:3,000) in
TTBSM. Bands were visualized by enhanced chemilumi-
nescence (ECL; Amersham, Arlington Heights, IL, USA)
and exposure to Fuji RX x-ray film. Semiquantification of
IGFBP bands was performed by scanning densitometry
(Bio-Rad GS 670 imaging densitometer).
Extraction of total RNA from tissues
After killing each rat, about 200 mg of tissue were
immediately collected in 3 ml of ice-cold 4 M guanidine
thiocyanate. The tissues were homogenized immediately
with an Ultra-Turrax TP10 N homogenizer (Ika Werk
Janke & Kunkel, Staufen, Germany), placed in liquid
nitrogen, and stored at 270°C. Extraction of total RNA
from the tissue homogenate was performed according to
Lowe et al [18] with minor modifications as described by
Ding et al [19]. One volume of tissue homogenate was
thoroughly mixed with 0.1 volume of 2 M sodium acetate, 1
volume of phenol and 0.2 volume of chloroform-isoamylal-
cohol (49:1). The preparation was centrifuged at 16,000 g
for 30 minutes at 4°C; the clear supernatant underwent
precipitation with 1 volume of isopropanol at 270°C for 60
minutes. After centrifugation at 14,000 g for 10 minutes at
4°C, the resulting pellet was washed in cold 75% ethanol,
air dried and resuspended in deionized formamide. The
quantity of RNA was determined by absorbance at 260 nm.
The quality of the samples was evaluated by visualizing the
18 S and 28 S ribosomal RNA after 3 mg total RNA was
separated in a 1% agarose/formaldehyde gel.
Solution hybridization/RNase protection assay
Rat DNA probes for the solution hybridization/RNase
protection assay of mRNAs for IGFBPs 1 through 6 were
kindly provided by Dr. Shimasaki (La Jolla, CA, USA). The
probes for b-actin and IGF-IR were a gift from Dr.
LeRoith (NIDDK, NIH, Bethesda, MD, USA). Another
125 bp probe for rat b-actin (b-actin 125; Ambion, Austin,
TX, USA) was also used for some of the assays. The
antisense RNA probes were synthesized and labeled using
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50 to 80 mCi (10 mCi/ml) [32P]UTP (ICN Pharmaceutical
Inc., Costa Mesa, CA, USA) and T7 (for IGFBP-1, 2, 4, 5,
6 and b-actin), Sp6 (for the IGF-IR) and T3 (for IGFBP-3)
polymerases with the Riboprobe Gemini II System (Pro-
mega Corporation, Madison, WI, USA) according to the
manufacturer’s instructions. The solution hybridization/
RNase protection assay was performed as described by
Ding et al [19] with the following minor modifications.
Briefly, 10 to 15 mg of total RNA was mixed with 29 ml of
hybridization buffer and 1 ml of probe mixture. The hybrid-
ization mixture was composed of 75% deionized form-
amide, 20 mM Tris pH 7.5, 1 mM EDTA pH 8.0, 0.4 M NaCl,
0.1% SDS and 1 to 5 3 105 cpm of the different antisense
RNA probes. After the mixture was incubated for 16 hours
at 60°C, samples were digested with 12 mg of RNase A and
0.6 mg of RNase T1 for one hour at 30°C. The protected
hybrids were extracted with phenol/chloroform, precipi-
tated with ethanol and separated on an 8% polyacryl-
amide/8 M urea denaturing gel. The amount of each
protected fragment was quantified by autoradiography and
scanning densitometry.
Statistical analyses
Data are expressed as mean 6 SEM. Differences between
groups of data obtained at the same time point were
compared by analysis of variance (SPSS software). For
serial measurements of each of the serum IGFBPs, analysis
of variance for repetitive measurements was used to test for
significant changes within each individual group over time.
If global statistical significance was observed (P , 0.05), the
presence of statistically significant differences between any
two groups, or between any two time points within the same
group was determined by the Scheffe test. Serum IGFBPs
were measured in five or six rats from each of the four
treatment groups. Unless otherwise stated, the IGFBP
mRNAs and IGF-IR mRNAs were measured in four rats
from each group.
RESULTS
The mean serum creatinine concentrations in the four
groups of rats are shown in Figure 1. The serum creatinine
followed a pattern similar to that previously described [8,
10–12]. After surgery, serum creatinine rose rapidly in the
two ARF groups. Serum creatinine concentrations were
similar in the two ARF groups at five hours, which was
immediately before the first rhIGF-I injection. The mean
serum creatinine levels in the ARF1V rats rose progres-
sively to a maximum of 6.57 6 0.59 mg/dl at 72 to 74 hours,
when the rats were killed. In the ARF1IGF rats, the mean
values for serum creatinine tended to plateau about 24
hours after surgery, and their maximum mean serum
creatinine value was 3.51 6 0.48 mg/dl at 48 hours after
surgery. At 24, 48 and 72 to 74 hours after surgery, serum
creatinine was significantly greater in the ARF1V rats than
in the ARF1IGF rats. Mean serum creatinine concentra-
tions in the ARF1IGF and ARF1V rats were also signif-
icantly greater than in either group of SO rats at each time
point after surgery (5, 24, 48 and 72 to 74 hr). Body weights
did not differ among the four groups of rats either imme-
diately before surgery or 72 to 74 hours postoperatively.
The Western ligand blots for serum IGFBPs 1 to 6, the
immunoblots for IGFBP-2, and the mean serum levels for
IGFBPs 1 to 4, all obtained serially throughout the 72 to 74
hours of study, are shown in Figures 2 and 3. There was a
31 kD IGFBP that reacted with the IGFBP-1 antibody in
the immunoblot and was therefore identified as IGFBP-1.
Serum IGFBP-1 concentrations fell significantly between
baseline (that is, immediately before surgery) and 72 to 74
hours in both the ARF and SO rats given vehicle. Serum
IGFBP-1 was also significantly lower at 72 to 74 hours in
these two groups of rats as compared to the ARF1IGF and
SO1IGF animals (Figs. 2A and 3A). Serum IGFBP-2 rose
above baseline values in the ARF and SO rats given
rhIGF-I (P , 0.05) and was significantly greater at 48 and
72 to 74 hours in the ARF1IGF rats than in each of the
other three groups (Figs. 2A and 3B). At 72 to 74 hours,
serum IGFBP-2 was also greater in the SO1IGF rats than
in the SO1V rats. The serum IGFBP-2 levels in the six rats
from each group, when measured by Western immuno-
blots, were similar to the values obtained by Western ligand
blotting. Therefore, a representative autoradiogram from
only one rat from each group is shown (Fig. 2B).
Fig. 1. Serum creatinine concentrations in rats with ischemic acute renal
failure (ARF) and sham operated (SO) control rats immediately before
surgery (0 time) and at 5, 24, 48 and 72 to 74 hours after surgery. The
ARF and SO rats were each randomized to receive subcutaneous injec-
tions of either recombinant human insulin-like growth factor-I (rhIGF-I),
50 mg/100 g, or vehicle (V; 0.9% saline) three times daily starting five
hours after surgery, immediately after the blood drawing. N 5 5 to 6 rats
per group. Triangles and squares represent mean values; brackets indicate
SEM. aP , 0.05 versus SO1IGF rats, bP , 0.05 versus SO1V rats and cP ,
0.05 versus each of the three other groups at the same time points.
Symbols are: (e) ARG1IGF; (f) ARF1V; () SO1IGF; () SO1V.
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Serum IGFBP-3 decreased during the course of study in
all groups except for the ARF1V rats (Figs. 2A and 3C).
The fall in IGFBP-3 was more pronounced in the SO1IGF
and the SO1V rats than in the ARF1IGF rats (P , 0.05).
At both 48 and 72 to 74 hours after surgery, serum
IGFBP-3 concentrations were greater in the ARF1V rats
than in any other of the three groups, and were higher in
the ARF1IGF rats than in either the SO1IGF or the
SO1V animals. Serum IGFBP-4 (24 kD) rose significantly
but transiently over baseline values, at five hours, in both
the ARF1IGF and ARF1V groups (Figs. 2A and 3D). At
this time, serum IGFBP-4 concentrations in each of these
groups were significantly greater than in the SO1IGF or
the SO1V rats. A faint band was visualized on Western
ligand blotting at about 29 kD (Fig. 2A). The time course
for the density of this band in each of the four groups of
rats was similar to that for serum IGFBP-4. Because of the
similar time course to IGFBP-4 and the greater molecular
weight of this ligand protein, this band may represent a
highly glycosylated form of IGFBP-4. No band that corre-
sponded to IGFBP-5 or IGFBP-6 was observed by Western
ligand blotting (Fig. 2A).
The mRNAs for IGFBPs-1 to -6 in renal cortex and
medulla, obtained 72 to 74 hours after surgery, are shown
in Figures 4 to 6. In renal cortex, there was a trend for the
mean values for the mRNAs for IGFBPs-2 to -6 to be lower
in the ARF1IGF and ARF1V rats than in the two SO
groups (Fig. 6A). There was a significantly lower gene
Fig. 2. Western ligand blot (WLB) and Western immunoblot (WIB) of serum insulin-like growth factor (IGF) binding proteins (IGFBPs) over time
for a representative rat from each of the four treatment groups. Sera were obtained from the four rats immediately before surgery (0 hr) and 5, 24, 48
and 72 to 74 hours after surgery, and processed as described in the methods section. WLB was used to assess the IGFBPs 1 to 6 (A). After WLB, the
same nitrocellulose membrane was washed and further processed for assay of IGFBP-2 by WIB analysis (B). The bars on the right indicate the location
of the various IGFBPs, and the bars on the left indicate the molecular size of the standard protein markers in kD. Six separate experiments were
performed with different rats from the four groups, and similar results were obtained.
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expression in renal cortex for IGFBP-3, IGFBP-4, and
IGFBP-6 in both groups of ARF rats as compared to either
the SO1IGF or the SO1V rats (Figs. 4 and 6A). In the
ARF1IGF rats, IGFBP-5 mRNA was also lower than in
either the SO1IGF or the SO1V rats. In the ARF1V rats,
there was significantly less expression in kidney cortex for
IGFBP-2 mRNA, as compared to the SO1V rats (Figs. 4
and 6A). There was no difference between the ARF1IGF
versus the ARF1V groups with regard to the gene expres-
sion for the IGFBPs in renal cortex. The mRNAs for
IGFBPs-4 and -6 were significantly lower in the SO1IGF
rats as compared to the SO1V animals.
In the renal medulla, the gene expression for IGFBPs-4
and -6 were significantly lower in the ARF1IGF and
ARF1V rats as compared to the SO1V animals (Figs. 5
and 6B). ARF1V rats displayed a lower IGFBP-6 mRNA
than did the SO1IGF animals. Also, ARF1IGF and
SO1IGF rats each demonstrated a lower IGFBP-2 mRNA
than did the SO1V rats (Figs. 5 and 6B).
There were no differences among the four groups of rats
in the mRNA for IGFBPs-1, -3 to -6 in the liver, obtained
72 to 74 hours after surgery (Fig. 7). On the other hand,
liver IGFBP-2 mRNA was significantly greater in both the
ARF1IGF rats and the SO1IGF animals than in either
Fig. 3. The time course of serum IGFBPs in the four groups of rats. Sera were drawn at the indicated times before and after surgery. Serum IGFBPs
were analyzed by Western ligand blots and scanning densitometry. In order to standardize the densitometry readings, the readings of the IGFBPs in
the sera obtained immediately before surgery (0 time) for each rat were arbitrarily defined as 1. The densitometry readings of the sera obtained at 5,
24, 48 and 72 to 74 hours after surgery from the same rats were expressed as a fraction of the 0 time levels. N 5 5 to 6 rats per group. Data are expressed
as mean 6 SEM. aP , 0.05 versus ARF1IGF group, cP , 0.05 versus SO1IGF, dP , 0.05 versus SO1V and eP , 0.05 versus each of the three other
groups at the same time points. fP , 0.05 versus values from the same group at zero time. Symbols are: (M) ARF1IGF; (f) ARF1V; () SO1IGF;
() SO1V.
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the ARF or the SO rats that received the vehicle (Figs. 7
and 8). IGFBP-2 mRNA values were approximately twice
as great in the two groups of rhIGF-I treated rats as
compared to the two groups of vehicle injected animals.
Thus, the increased liver IGFBP-2 mRNA levels parallel
the elevated serum IGFBP-2 concentrations in the ARF
and SO rats given rhIGF-I.
At 72 to 74 hours, the mRNAs for IGFBPs-3 to -6 were
not different in heart, lung and quadriceps muscle among
the four groups of rats (data for lung are shown in Fig. 9).
IGFBP-1 and -2 mRNAs were examined (and detected) in
heart, lung and quadriceps muscle from only one or two
rats per group and therefore could not be evaluated for
differences between the four treatment groups.
The mRNA values for the IGF-IR in both renal cortex
and renal medulla, obtained 72 to 74 hours after surgery,
are shown in Figures 4 and 5. In both renal cortex and
medulla, the IGF-IR mRNA was significantly lower in both
the ARF1IGF and the ARF1V rats as compared to each
of the two SO groups (Fig. 10). In both renal cortex and
medulla, there was no difference between the two ARF
groups or between the two SO groups with regard to
IGF-IR mRNA. The reduction in IGF-IR mRNA in the
ARF1IGF and ARF1V rats appeared to be more marked
in the renal medulla than in the cortex. Although IGF-IR
mRNA was examined in the liver in four rats from each of
the four treatment groups, no IGF-IR mRNA was detected
in any rat. IGF-IR was also detected in heart, lung and
quadriceps muscle from each of the one or two rats studied
in each of the four treatment groups.
DISCUSSION
IGF-I is a growth factor that stimulates replication and
differentiation of renal tubular cells [5]. In rats with ARF
caused by ischemia or certain toxins, the renal concentra-
tions of the IGF-I peptide and IGF-I mRNA are reduced
[12–14]. However, immunohistochemical and in situ hybrid-
ization studies indicate that the IGF-I peptide and IGF-I
Fig. 4. Representative autoradiograms of hybridization/RNase protection assays of mRNAs for IGFBPs-1 to -6, and IGF-I receptor (IGF-IR) in kidney
cortex obtained from the four groups of rats. Fifteen micrograms of total RNA were cohybridized with different cRNA probes and processed as
described in the Methods section. The bars on the right indicate the location of different mRNAs for IGFBPs, IGF-IR and b-actin. The bars on the
left show the size of the mRNAs in terms of base pairs. Four rats were studied from each group.
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mRNA are transiently expressed in regenerating tubular
cells that normally may not express this peptide [7]. More-
over, in rats with ARF caused by ischemia or certain toxins,
rhIGF-I administration accelerates recovery of renal func-
tion [8–12]. Taken together, these observations suggest
that IGF-I may play a role in the recovery of ARF caused
by ischemia or nephrotoxicity.
It has been suggested that the increase in the abundance
and binding affinity of the IGF-IR in the injured regener-
ating kidney may influence the actions of IGF-I [7]. Despite
much research, the role of the IGFBPs in the regulation of
IGF-I activity is not well defined. It has been proposed that,
under certain circumstances, these binding proteins may
reduce the availability of IGF-I to the target cell, increase
the half-life of serum IGF-I, serve as a reservoir for this
peptide, and facilitate the delivery of IGF-I to the target
cells [3]. In some conditions, IGFBPs may potentiate the
actions of IGF-I [20, 21]. Furthermore, some IGFBPs may
have direct cellular effects that are independent of IGF-I
[22, 23]. These observations suggest that it is important to
elucidate the gene expression of the six IGFBPs and of the
IGF-IR in the acutely ischemic kidney in order to assess the
potential actions of these proteins as well as the role of
IGF-I.
ARF engenders a catabolic response in rats that can be
ameliorated by the administration of rhIGF-I [8]. Hence, it
was also considered important to examine the gene expres-
sion for IGFBPs and IGF-IR in other tissues of rats with
ischemic ARF. Finally, since the exogenous administration
of rhIGF-I has beneficial effects on the course of ARF in
the rat, we believed that it is important to examine the
effects of rhIGF-I on the gene expression of these poten-
tially regulatory proteins. We have previously shown that in
ARF and SO rats treated by the current protocol, serum
IGF-I levels do not change when the animals are injected
with vehicle and rise to about twice baseline values when
they are given rhIGF-I [8].
The results of the present study indicate that ARF and
treatment with rhIGF-I each affected the concentrations of
certain IGFBPs in serum and IGFBP mRNAs or IGF-IR
mRNA in kidney or liver, and that for certain proteins
there was an interaction between ARF and rhIGF-I. At 72
to 74 hours after surgery, treatment with rhIGF-I had a
greater influence on serum IGFBP-1 and -2 levels than did
the presence of ARF. Serum levels of these binding pro-
teins were higher in the ARF and SO rats given rhIGF-I
than in the two groups given vehicle (Fig. 3 A and B).
Moreover, serum IGFBP-2 levels at 48 and 72 to 74 hours
were significantly greater in the ARF rats given rhIGF-I
than in the SO animals receiving rhIGF-I. IGFBP-3 values
were greater in the two groups of ARF rats and were higher
in the ARF1V animals. Serum IGFBP-3 concentrations
Fig. 5. Autoradiograms of mRNAs for IGFBPs-1 to -6 and IGF-IR from kidney medulla detected by hybridization/RNase protection assays. The
methods and symbols are as described in Figure 4.
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Fig. 6. Relative mRNA levels for IGFBPs 1 to 6 from kidney cortex (A) and medulla (B). mRNA levels were detected by hybridization/RNase protection
assays and adjusted for the b-actin signal. The autoradiograms presented in Figure 4 and 5 were analyzed by scanning densitometry. The average of the
SO1V values for each mRNA was then assigned an arbitrary unit of one, and the values from the other three groups were expressed relative to this
unit. Results are from 4 rats per group. Data are expressed as mean 6 SEM. aP , 0.05 versus SO1V, bP , 0.05 versus SO1IGF, cP , 0.05 versus each
of the other three groups.
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were also affected by both ARF and rhIGF-I. Serum
IGFBP-4 levels rose transiently only in the two groups of
rats with ARF, independently of whether the rats received
rhIGF-I or vehicle.
In renal cortex 72 to 74 hours after surgery, most of the
IGFBP mRNAs were reduced in the ARF groups as
compared with both groups of SO animals (Figs. 4 and 6A).
In renal medulla as compared to the SO1V animals, both
groups of ARF rats displayed decreased mRNAs for
IGFBPs-4 and -6 and the ARF1IGF and SO1IGF rats
showed reduced mRNA for IGFBP-2 (Figs. 5 and 6B).
ARF was associated with lower levels of IGF-IR mRNA in
both renal cortex and medulla (Figs. 4, 5 and 10), whereas
treatment with rhIGF-I had no effect on gene transcription
for this receptor. In the extrarenal tissues studied (liver,
lung, heart and quadriceps muscle), neither ARF nor
rhIGF-I treatment appeared to affect the mRNA for the six
IGFBPs with the exception of IGFBP-2 mRNA in liver.
Moreover, IGF-IR mRNA was not detected in liver in any
rat from any of the four treatment groups. Since the mRNA
for IGFBP-I, IGFBP-2 and for IGF-IR were only measured
in heart, lung and quadriceps muscle from one or two rats
in each group, the values for these mRNAs cannot be
interpreted.
To our knowledge these are the first studies to describe
the effects of either experimental ARF or the combination
of experimental ARF and rhIGF-I treatment in rats on
serum IGFBPs, IGFBP mRNAs in several extrarenal tis-
sues, and IGF-IR mRNA in liver. These are also the first
studies of the effects of rhIGF-I on gene expression in the
kidney for IGFBPs and IGF-IR in ischemic ARF.
It is intriguing that at 72 to 74 hours after surgery, liver
IGFBP-2 mRNA levels were increased in the two groups of
rats receiving rhIGF-I and were not affected by ARF (Figs.
7 and 8). The increased IGFBP-2 gene expression in the
rhIGF-I treated rats may account for the rise in serum
IGFBP-2 in these two groups of rats (Figs. 2 and 3). It is
pertinent that injection of healthy adults with rhIGF-I
increases circulating IGFBP-2 levels [24]. The mechanism
Fig. 7. Representative autoradiogram of mRNAs for IGFBPs-1 to -6 from
liver detected by the hybridization/RNase protection assay. The methods
and symbols are as described in Figure 4.
Fig. 8. Relative mRNA levels for IGFBP-2 from liver. mRNA levels were
detected by hybridization/RNase protection assays and adjusted for the
b-actin signal. The autoradiograms presented in Figure 7 were analyzed
by scanning densitometry. The average of the SO1V values for IGFBP-2
mRNA was then assigned an arbitrary unit of one, and the values from the
other three groups were expressed relative to this unit. Results are from
four rats per group. Data are expressed as mean 6 SEM. aP , 0.05 versus
ARF1V, bP , 0.05 versus SO1V.
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for the increased hepatic IGFBP-2 mRNA may involve the
effects of rhIGF-I on growth hormone, and insulin. These
two hormones decrease the hepatic gene expression and
serum concentrations of IGFBP-2 [25]. RhIGF-I sup-
presses serum concentrations of these hormones [26–28].
Thus, a decrease in serum growth hormone and insulin
induced by rhIGF-I might lead to desuppression of hepatic
IGFBP-2 mRNA.
The lack of decrease in serum IGFBP-1 concentrations
in the ARF and SO rats given rhIGF-I, in contrast to those
treated with vehicle, may also be explained by the effects of
this hormone (Figs. 2A and 3A). In normal humans who
are calorie-restricted, rhIGF-I increases serum IGFBP-1
[29], whereas growth hormone suppresses serum IGFBP-1
concentrations [29]. rhIGF-I also suppresses growth hor-
mone secretion [28], which may contribute to the elevation
in serum IGFBP-1.
Serum IGFBP-3 concentrations decrease with dietary
protein deprivation in rats [30] and calorie restriction in
humans [31]. This may explain the reduction in serum
IGFBP-3 in the two groups of SO rats that were fasted
except for dextrose monohydrate added to the drinking
water. It is not clear why serum IGFBP-3 did not decrease
in the two groups of ARF rats that were similarly fasted.
IGFBP-3 is glycosylated and has a molecular weight of
about 46 to 53 kD. It binds in plasma with IGF-I and a
glycoprotein referred to as the acid labile subunit to form a
complex with a molecular weight of about 150 kD [32].
Both IGFBP-3 and the IGFBP-3 150 kD complex are too
large to be excreted or catabolized significantly by the
normal kidney. Thus, the preservation of the serum levels
in the ARF rats, as compared to the SO animals, would not
be expected to be due to a reduction in renal degradation
or urinary excretion of IGFBP-3. Serum growth hormone is
increased in ARF [33, 34], and growth hormone stimulates
the secretion of IGFBP-3 [30]. Thus, elevated growth
hormone levels might account for the maintenance of
serum IGFBP-3 in the ARF rats. The ability of rhIGF-I to
suppress growth hormone secretion [28] may also explain
why serum IGFBP-3 was higher in the ARF1V rats as
compared to the ARF1IGF animals (Figs. 2 and 3C).
Since serum IGFBPs are considered to be derived, at
least to a substantial degree, from the liver, it is puzzling
that the mRNAs in liver for IGFBP-1 and -3 were not
different in the four groups of rats at 72 to 74 hours after
surgery although the serum IGFBP-1 and -3 concentrations
did differ. This discrepancy might be explained by the fact
that the IGFBP mRNAs were only measured at one point
in time and that the hepatic IGFBP mRNA levels may not
correlate precisely with the synthesis of these proteins.
Moreover, serum IGFBPs concentrations also could be
influenced by degradation and compartmental distribution
of these compounds.
The results of this study are similar to other investiga-
tions in rats with ischemic, mercuric chloride or folic acid
induced ARF or ischemic acute renal injury [12–14, 35].
Most reports of renal IGFBP mRNAs -2, -3, and -5 showed
decreased levels, particularly on days 2 and 3 after the onset
of ARF [13, 14, 35], although in one report, IGFBP-2 was
increased on day 1 [14]. In various studies, renal IGFBP-1
mRNA was unchanged or increased in ARF [12–14, 35].
We also found renal cortical and medullary IGFBP-I
Fig. 9. Representative autoradiograms of mRNAs for IGFBPs-2 to -6 and
IGF-IR from lung determined by hybridization/RNase protection assays.
For IGFBPs-3 to -6, four rats were analyzed from each group; for
IGFBP-2 and IGF-IR, only two rats from each group were analyzed.
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mRNA levels in the ARF rats to be not different from the
SO animals. In contrast to our findings, Friedlander and
coworkers found IGFBP-1 mRNA to be elevated to a
similar degree in ARF rats given rhIGF-I as compared to
ARF rats not receiving this hormone [12]. IGFBP-4 mRNA
was reduced or not different from SO values on days 1 to 3
of ARF [14, 35]. By day 7, the mRNA for most of these
IGFBPs was not different from the SO values or was
increased. Renal IGFBP-6 mRNA also was reported to be
unchanged for three days after the onset of folic acid-
induced renal failure [14].
In these latter studies there were no changes in IGF-IR
mRNA in whole kidney at different time points after the
induction of ARF [12–14, 35]. An exception was the study
of Hise et al, who observed increased IGF-IR mRNA on
day 1 after the onset of ARF and no change in the IGF-IR
gene expression on days 2 and 3 [14]. In contrast, we
observed a decrease in IGF-IR mRNA in both renal cortex
and medulla. As with the study of Friedlander et al [12], we
observed that rhIGF-1 treatment for three days had no
effect on gene expression for this receptor. In a previous
unrelated study of ARF rats from our laboratory, Ding et al
also found that renal cortical IGF-IR mRNA was de-
creased in comparison to preoperative levels or to SO rats
studied at the same time point, on days 1, 3 and 5, and was
increased on day 7 after the onset of the ischemic ARF
[36]. Rather similar findings were observed for renal med-
ullary IGF-IR in these ARF rats [36]. Interestingly, Tsao
and coworkers [13] and Fervenza, Tsao and Rabkin [35]
observed an increase in the IGF-IR number in the injured
kidney, suggesting a post-translational up-regulation of the
receptor protein.
The causes for the discrepant results are unclear. The
times of measurements of renal IGF-IR mRNA or IGFBP
mRNAs in these other studies were at one, two, three or
seven days after the onset of ARF [12–14, 35], whereas in
the present study the renal mRNAs were measured only at
72 to 74 hours after surgery. The methods of measurements
of the IGFBP mRNAs and IGF-IR mRNA were similar in
most of these studies. However, IGFBP mRNAs were
measured separately in renal cortex and medulla only in
our study, and IGF-IR mRNA was measured separately in
the renal cortex and medulla only in the present study and
also by Ding et al [36] from our laboratory. In the other
studies, the IGFBP mRNAs and IGF-IR were measured in
the whole kidney [12–14, 35]. In two of these studies, ARF
was induced by a nephrotoxin [12, 14], whereas in the
present study, ARF was induced by ischemia.
The variation in nutrient intakes after creation of ARF
also might contribute to some of the differences in the
results from these studies. In rats that do not have ARF,
fasting or protein deprivation engenders serum concentra-
tions and hepatic gene expressions that are increased for
IGFBP-1 and reduced for IGFBP-3 [30, 37]. In the normal
kidney, fasting apparently does not affect mRNA for
IGFBPs-2 to -5 [38], whereas low protein diets decrease
IGFBP-2 mRNA [37]. The effects of different nutrient
intakes on the gene expression and concentrations of
IGFBPs or IGF-IR in ARF are unknown. In many of the
previous studies, rats with ARF were allowed to eat ad
libitum [7, 10–14]. In the present study, all rats were fasted
for the 72 to 74 hours after surgery, except for 5% dextrose
monohydrate in drinking water. We adopted this study
design in order to avoid the possibility that the fasting ARF
Fig. 10. Relative IGF-IR mRNA levels from kidney cortex (A) and
medulla (B). The autoradiograms presented in Figures 4 and 5 were
analyzed by scanning densitometry and adjusted for the b-actin signal. The
average of the mRNA values in each SO1V rat was then assigned an
arbitrary unit of one, and the values from the other three groups were
expressed relative to this unit. Results are from four rats per group. Data
are expressed as mean 6 SEM. aP , 0.05 versus SO1IGF, bP , 0.05 versus
SO1V.
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or SO rats given rhIGF-I might develop hypoglycemia and,
at the same time, to give all rats in the study approximately
the same nutrient intake. Rats were not given access to a
complete diet because we have previously observed that
rats with severe ARF caused by a surgical procedure eat
very little, if at all, and have poor gastric emptying. Thus, to
allow the rats to eat could have led to marked variations
from rat to rat in nutrient intake and absorption. This might
have made it difficult, if not impossible, to perform accu-
rate comparisons between groups in our study or between
our study and other studies.
It is also of potential importance that the magnitude of
acute renal failure varied in these studies [12–14, 35]. The
maximum serum creatinine concentrations were greatest in
the present study, which suggests that the renal injury may
have been more severe. Also, in the study of Fervenza et al,
only one kidney was made ischemic, and the rats did not
develop uremia [35]. We elected to create a rather severe
model of ARF, in order to more closely resemble the
patient with severe ARF, because these are the individuals
who tend to have the highest morbidity and mortality and
for whom the clinician may have the greatest interest in
understanding the pathophysiology of the ARF and in
developing methods of treatment.
The reduction in the mRNA for several IGFBPs and for
IGF-IR in renal cortex and medulla suggests that the
concentrations of these binding proteins and of IGF-IR
may also be reduced in these tissues. Since binding proteins
and IGF-IR may have regulatory effects on the actions of
IGF-I and IGF-II [20, 39, 40], changes in binding protein
and IGF-IR concentrations might affect the ability of the
kidney to recover from ARF. A reduced tissue IGF binding
capacity might increase the effects of these growth factors
by making them more available to tissues [39]. Alterna-
tively, decreased binding capacity might reduce the actions
of these growth factors by trapping lesser amounts of the
growth factors in kidney tissue of by reducing the facilita-
tive effects of IGFBPs on IGF-I that have been described
under some circumstances [20, 40]. Similarly, a decrease in
IGF-IR may reduce the actions of IGF-I or IGF-II in the
acutely injured kidney. The results of the present study also
indicate that administration of IGF-I may alter the gene
expression and possibly the concentrations of certain bind-
ing proteins. Further research, including actual measure-
ments of IGF binding proteins and the IGF-IR in kidney
tissue, may be necessary to resolve these questions.
In summary, the present study indicates that ARF and
rhIGF-I both independently and conjointly affect serum
IGFBP concentrations. ARF affects the gene expression in
kidney for IGFBPs-1 to -6 and IGF-IR, whereas rhIGF-I
enhances hepatic IGFBP-2 mRNA and possibly suppresses
renal medullary IGFBP-2 mRNA. This study, in conjunc-
tion with other published research, suggests the possibility
that the effects of ARF or rhIGF-I may be influenced by
the type and severity of the renal injury and the nutritional
intake of the animal. The clinical effects of these alterations
on the serum concentrations of IGFBPs and the gene
expression of IGFBPs and IGF-IR remain to be elucidated.
Reprint requests to Joel D. Kopple, M.D., Harbor-UCLA Medical Center,
1000 West Carson Street, Torrance, California 90509, USA.
APPENDIX
Abbreviations used in this article are: ARF, acute renal failure; BSA,
bovine serum albumin; GFR, glomerular filtration rate; IGF, insulin-like
growth factor; IGFBP, insulin-like growth factor-I binding protein; IGF-
IR; insulin-like growth factor type I receptor; rhIGF-I, recombinant
human IGF-1; TBS, Tris buffered saline; TBSM, TBS buffer with nonfat
dry milk; TTBS, Tris buffer with Tween 20; SO, sham operated; V, vehicle
with 9% saline.
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